Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 663-668

  Kawajiri, Hidemi ^a   Takashima, Tsutomu ^a   Aomatsu, Naoki ^a   Kashiwagi, Shinichiro ^a   Noda, Satoru ^a   Onoda, Naoyoshi ^a   Ishikawa, Tetsurou ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Triple negative subtype

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; OVERALL SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY;

EID: 84893006711     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1792     Document Type: Article

References (23)

1. Wolmark N, Wang J, Mamonas E and Fisher B: Preoperative chemotherapy in patients with operative breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102, 2001.
2. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27. J Crin Oncol 21: 4165-4174, 2003.
3. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
4. Ring AE, Smith IE, Ashley S, Fulford LG and Lakhani SR: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91: 2012-2017, 2004.
5. Fasching PA, Heusinger K, Haeberle L, et al: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11: 486, 2011.
6. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804, 2012.
7. Kawajiri H, Takashima T, Onoda N, et al: Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol Lett 4: 612-616, 2012.
8. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 2676-2685, 2005.
9. The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. 16th edition. Kanehara Shuppan, pp60, 2008.
10. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007.
11. Keskin S, Muslumanoglu M, Saip P, et al: Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology 81: 30-38, 2011.
12. Tan MC, Al Mushawah F, Gao F, et al: Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 198: 520-525, 2009.
13. Jones RL, Salter J, A'Hern R, et al: Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119: 315-323, 2010.
14. Colleoni M, Bagnardi V, Rotmensz N, et al: Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116: 359-369, 2009.
15. Toi M, Nakamura S, Kuroi K, et al: Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110: 531-539, 2008.
16. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13: 228-233, 2007.
17. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53, 2008.
18. Colleoni M, Giobbie-Hurder A, Regan MM, et al: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG1-98 study. J Clin Oncol 29: 1117-1124, 2011.
19. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377: 321-331, 2011.
20. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12: 236-244, 2011.
21. Wolstenholme V, Hawkins M, Ashley S, Tait D and Ross G: HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 17: 661-665, 2008.
22. Aoyama H: Radiation therapy for brain metastases in breast cancer patients. Breast Cancer 18: 244-251, 2011.
23. Matsumoto K, Ando M, Yamauchi C, et al: Questionnaire survey of treatment choice for breast cancer patients with brain metastasis in Japan: results of a nationwide survey by the task force of the Japanese Breast Cancer Society. Jpn J Clin Oncol39: 22-26, 2009.